MBSAsia, Ltd.


Welcome to MBSAsia, Ltd., a wholly owned subsidiary of Maine Biotechnology Services, Inc., Portland, Maine, USA.

MBS and MBSAsia are your providers of hybridoma development; polyclonal and monoclonal antibody production and purification; and immunoassay optimization.

MBSAsia is located at the Thailand Science Park in Pathumthani, Thailand just 45K north of Bangkok. MBSAsia is proud to be a BOI (Board of Investment of Thailand) company.

Modeling itself after its parent company, MBSAsia plans to become a leading contract immunobiological service and antibody contract manufacturer. For 18 years, MBS has been a dependable partner in research, development, and large-scale production

Services provided in our cGMP facility include hybridoma development, polyclonal antibody development, ascites and in vitro production and antibody purification. MBS also offers a large selection of bulk < OEM monoclonal and polyclonal antibodies for diagnostic, pharmaceutical and research applications.

MBSAsia invites you to browse our sites and learn more about the services and products we offer. We look forward to working with you on your specific antibody needs, and providing you feedback on your project. We are dedicated to supplying you with the utmost in quality. We know your research depends on it.

Initiation Immunization Fusion Subcloning Antibody Production Search Contact
MBS expands Osteopontin Products

Osteopontin (OPN) is a well-characterized secreted protein found in the circulation and is emerging as a potential biomarker for many cancers. Maine Biotechnology Services, Inc.(MBS), developed seven anti-human OPN monoclonal Antibodies, recognizing the C terminal, N Terminal and DSVVYG peptide.

MBS is Offering New Monoclonal Antibodies to PEG

Maine Biotechnology Services has developed two antibodies that recognize the linear backbone of Polyethylene glycol (PEG). There are broad applications for these antibodies in both production and R&D settings. Our PEG antibodies can be a vital tool for propelling therapeutics to market by serving as a positive control anti-drug antibody, measuring clearance of a drug, or simply in a western blot as a QA release confirming PEGylation.

MBS Adds two Antibodies to Human Myeloperoxidase

MBS R&D is introducing two new anti-human Myeloperoxidase monoclonal antibodies. Contact us to order the two antibodies recognizing Myeloperoxidase (MPO), a well documented biomarker for immune deficiency and myocardial infarction. The antibodies were developed in-house and validated as a matched pair in a sandwich ELISA format.